These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1099 related items for PubMed ID: 25315243

  • 1. Can complementary 68Ga-DOTATATE and 18F-FDG PET/CT establish the missing link between histopathology and therapeutic approach in gastroenteropancreatic neuroendocrine tumors?
    Has Simsek D, Kuyumcu S, Turkmen C, Sanlı Y, Aykan F, Unal S, Adalet I.
    J Nucl Med; 2014 Nov; 55(11):1811-7. PubMed ID: 25315243
    [Abstract] [Full Text] [Related]

  • 2. Prospective Study of 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography for Detecting Gastro-Entero-Pancreatic Neuroendocrine Tumors and Unknown Primary Sites.
    Sadowski SM, Neychev V, Millo C, Shih J, Nilubol N, Herscovitch P, Pacak K, Marx SJ, Kebebew E.
    J Clin Oncol; 2016 Feb 20; 34(6):588-96. PubMed ID: 26712231
    [Abstract] [Full Text] [Related]

  • 3. Comparison of the Impact of 68Ga-DOTATATE and 18F-FDG PET/CT on Clinical Management in Patients with Neuroendocrine Tumors.
    Panagiotidis E, Alshammari A, Michopoulou S, Skoura E, Naik K, Maragkoudakis E, Mohmaduvesh M, Al-Harbi M, Belda M, Caplin ME, Toumpanakis C, Bomanji J.
    J Nucl Med; 2017 Jan 20; 58(1):91-96. PubMed ID: 27516446
    [Abstract] [Full Text] [Related]

  • 4. Dual tracer functional imaging of gastroenteropancreatic neuroendocrine tumors using 68Ga-DOTA-NOC PET-CT and 18F-FDG PET-CT: competitive or complimentary?
    Naswa N, Sharma P, Gupta SK, Karunanithi S, Reddy RM, Patnecha M, Lata S, Kumar R, Malhotra A, Bal C.
    Clin Nucl Med; 2014 Jan 20; 39(1):e27-34. PubMed ID: 24217539
    [Abstract] [Full Text] [Related]

  • 5. Clinical and Prognostic Value of PET/CT Imaging with Combination of 68Ga-DOTATATE and 18F-FDG in Gastroenteropancreatic Neuroendocrine Neoplasms.
    Zhang P, Yu J, Li J, Shen L, Li N, Zhu H, Zhai S, Zhang Y, Yang Z, Lu M.
    Contrast Media Mol Imaging; 2018 Jan 20; 2018():2340389. PubMed ID: 29681780
    [Abstract] [Full Text] [Related]

  • 6. MIB-1 Index-Stratified Assessment of Dual-Tracer PET/CT with 68Ga-DOTATATE and 18F-FDG and Multimodality Anatomic Imaging in Metastatic Neuroendocrine Tumors of Unknown Primary in a PRRT Workup Setting.
    Sampathirao N, Basu S.
    J Nucl Med Technol; 2017 Mar 20; 45(1):34-41. PubMed ID: 28154019
    [Abstract] [Full Text] [Related]

  • 7. High prognostic value of 18F-FDG PET for metastatic gastroenteropancreatic neuroendocrine tumors: a long-term evaluation.
    Bahri H, Laurence L, Edeline J, Leghzali H, Devillers A, Raoul JL, Cuggia M, Mesbah H, Clement B, Boucher E, Garin E.
    J Nucl Med; 2014 Nov 20; 55(11):1786-90. PubMed ID: 25286923
    [Abstract] [Full Text] [Related]

  • 8. Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (DOTA-DPhe1,Tyr3-octreotate) and 18F-FDG.
    Kayani I, Bomanji JB, Groves A, Conway G, Gacinovic S, Win T, Dickson J, Caplin M, Ell PJ.
    Cancer; 2008 Jun 20; 112(11):2447-55. PubMed ID: 18383518
    [Abstract] [Full Text] [Related]

  • 9. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.
    Thapa P, Ranade R, Ostwal V, Shrikhande SV, Goel M, Basu S.
    Nucl Med Commun; 2016 Oct 20; 37(10):1030-7. PubMed ID: 27243215
    [Abstract] [Full Text] [Related]

  • 10. Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors.
    Wild D, Bomanji JB, Benkert P, Maecke H, Ell PJ, Reubi JC, Caplin ME.
    J Nucl Med; 2013 Mar 20; 54(3):364-72. PubMed ID: 23297077
    [Abstract] [Full Text] [Related]

  • 11. Dual Somatostatin Receptor/18F-FDG PET/CT Imaging in Patients with Well-Differentiated, Grade 2 and 3 Gastroenteropancreatic Neuroendocrine Tumors.
    Metser U, Nunez JE, Chan D, Kulanthaivelu R, Murad V, Santiago AT, Singh S.
    J Nucl Med; 2024 Oct 01; 65(10):1591-1596. PubMed ID: 39266292
    [Abstract] [Full Text] [Related]

  • 12. The Impact of 68Ga-DOTATATE PET/CT Imaging on Management of Patients with Neuroendocrine Tumors: Experience from a National Referral Center in the United Kingdom.
    Skoura E, Michopoulou S, Mohmaduvesh M, Panagiotidis E, Al Harbi M, Toumpanakis C, Almukhailed O, Kayani I, Syed R, Navalkissoor S, Ell PJ, Caplin ME, Bomanji J.
    J Nucl Med; 2016 Jan 01; 57(1):34-40. PubMed ID: 26471695
    [Abstract] [Full Text] [Related]

  • 13. A comparison of 68Ga-DOTATATE and 18F-FDG PET/CT in pulmonary neuroendocrine tumors.
    Kayani I, Conry BG, Groves AM, Win T, Dickson J, Caplin M, Bomanji JB.
    J Nucl Med; 2009 Dec 01; 50(12):1927-32. PubMed ID: 19910422
    [Abstract] [Full Text] [Related]

  • 14. The Correlation Between [68Ga]DOTATATE PET/CT and Cell Proliferation in Patients With GEP-NENs.
    Yu J, Li N, Li J, Lu M, Leal JP, Tan H, Su H, Fan Y, Zhang Y, Zhao W, Zhu H, Pomper MG, Zhou Y, Yang Z.
    Mol Imaging Biol; 2019 Oct 01; 21(5):984-990. PubMed ID: 30796708
    [Abstract] [Full Text] [Related]

  • 15. Safety and Efficacy of 68Ga-DOTATATE PET/CT for Diagnosis, Staging, and Treatment Management of Neuroendocrine Tumors.
    Deppen SA, Liu E, Blume JD, Clanton J, Shi C, Jones-Jackson LB, Lakhani V, Baum RP, Berlin J, Smith GT, Graham M, Sandler MP, Delbeke D, Walker RC.
    J Nucl Med; 2016 May 01; 57(5):708-14. PubMed ID: 26769865
    [Abstract] [Full Text] [Related]

  • 16. Feasibility of Radio-Guided Surgery with ⁶⁸Gallium-DOTATATE in Patients with Gastro-Entero-Pancreatic Neuroendocrine Tumors.
    Sadowski SM, Millo C, Neychev V, Aufforth R, Keutgen X, Glanville J, Alimchandani M, Nilubol N, Herscovitch P, Quezado M, Kebebew E.
    Ann Surg Oncol; 2015 Dec 01; 22 Suppl 3(Suppl 3):S676-82. PubMed ID: 26350374
    [Abstract] [Full Text] [Related]

  • 17. Evaluation of neuroendocrine liver metastases: a comparison of dynamic contrast-enhanced magnetic resonance imaging and positron emission tomography/computed tomography.
    Armbruster M, Sourbron S, Haug A, Zech CJ, Ingrisch M, Auernhammer CJ, Nikolaou K, Paprottka PM, Rist C, Reiser MF, Sommer WH.
    Invest Radiol; 2014 Jan 01; 49(1):7-14. PubMed ID: 24002080
    [Abstract] [Full Text] [Related]

  • 18. Comparison of ⁶⁸Ga-DOTATATE PET-CT, ¹⁸F-FDG PET-CT and 99mTc-(V)DMSA scintigraphy in the detection of recurrent or metastatic medullary thyroid carcinoma.
    Ozkan ZG, Kuyumcu S, Uzum AK, Gecer MF, Ozel S, Aral F, Adalet I.
    Nucl Med Commun; 2015 Mar 01; 36(3):242-50. PubMed ID: 25369749
    [Abstract] [Full Text] [Related]

  • 19. The comparison of three different molecular imaging methods in localization and grading of insulinoma.
    Chang L, Bi X, Li S, Tong Q, Gu Y, He Z, Li Y, Chen Q, Cui J, Yu H, He Q, Liu M.
    Front Endocrinol (Lausanne); 2023 Mar 01; 14():1163176. PubMed ID: 37455905
    [Abstract] [Full Text] [Related]

  • 20. Quantitative and qualitative intrapatient comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: net uptake rate for accurate quantification.
    Velikyan I, Sundin A, Sörensen J, Lubberink M, Sandström M, Garske-Román U, Lundqvist H, Granberg D, Eriksson B.
    J Nucl Med; 2014 Feb 01; 55(2):204-10. PubMed ID: 24379222
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 55.